β-lactam antibiotics to prevent ventilator-associated pneumonia (VAP) in coma patients: A systematic review and meta-analysis of randomized controlled trials.

Medicina intensiva Pub Date : 2025-03-25 DOI:10.1016/j.medine.2025.502199

Edinson Dante Meregildo-Rodriguez, Mariano Ortiz-Pizarro, Martha Genara Asmat-Rubio, Carlos Geraldo Fernandez-Narváez, Gustavo Adolfo Vásquez-Tirado

{"title":"β-lactam antibiotics to prevent ventilator-associated pneumonia (VAP) in coma patients: A systematic review and meta-analysis of randomized controlled trials.","authors":"Edinson Dante Meregildo-Rodriguez, Mariano Ortiz-Pizarro, Martha Genara Asmat-Rubio, Carlos Geraldo Fernandez-Narváez, Gustavo Adolfo Vásquez-Tirado","doi":"10.1016/j.medine.2025.502199","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the effect of parenteral β-lactam antibiotics on outcomes related to ventilator-associated pneumonia (VAP) in adult patients in coma due to acute brain injury (ABI).Design: Systematic review and meta-analysis.Setting: Randomized controlled trials (RCTs) published up toSeptember 30, 2024.Patients or participants: Adult patients in coma due to ABI.Interventions: Parenteral β-lactam antibiotics.Main variables of interest: Incidence and outcomes related to VAP.Results: Three RCTs involving 483 patients met inclusion criteria; 231 patients received β-lactam prophylaxis. Among these, there were 115 cases of early-onset VAP (EO-VAP), 49 of late-onset VAP (LO-VAP), and 102 deaths. All studies were conducted in Europe. Causes of coma included trauma, stroke, and CO poisoning. Intravenous β-lactams (ampicillin/sulbactam, cefuroxime, and ceftriaxone) reduced EO-VAP risk by 57% (RR 0.43; 95% CI 0.30-0.61), and all-VAP by 35% (RR 0.65; 95% CI 0.53-0.80). No impact was observed on LO-VAP (RR 0.95; 95% CI 0.54-1.67), 28-day mortality (RR 0.76; 95% CI 0.53-1.09), intubation duration (SMD -0.13; 95% CI -0.46-0.21), or ICU length of stay (SMD -0.22; 95% CI -0.55-0.12). Heterogeneity and the risk of bias were low, with high overall evidence certainty.Conclusions: In adult patients in coma due to ABI, intravenous β-lactam antibiotics reduce EO-VAP and all-VAP risk.","PeriodicalId":94139,"journal":{"name":"Medicina intensiva","volume":" ","pages":"502199"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina intensiva","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medine.2025.502199","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the effect of parenteral β-lactam antibiotics on outcomes related to ventilator-associated pneumonia (VAP) in adult patients in coma due to acute brain injury (ABI).

Design: Systematic review and meta-analysis.

Setting: Randomized controlled trials (RCTs) published up toSeptember 30, 2024.

Patients or participants: Adult patients in coma due to ABI.

Interventions: Parenteral β-lactam antibiotics.

Main variables of interest: Incidence and outcomes related to VAP.

Results: Three RCTs involving 483 patients met inclusion criteria; 231 patients received β-lactam prophylaxis. Among these, there were 115 cases of early-onset VAP (EO-VAP), 49 of late-onset VAP (LO-VAP), and 102 deaths. All studies were conducted in Europe. Causes of coma included trauma, stroke, and CO poisoning. Intravenous β-lactams (ampicillin/sulbactam, cefuroxime, and ceftriaxone) reduced EO-VAP risk by 57% (RR 0.43; 95% CI 0.30-0.61), and all-VAP by 35% (RR 0.65; 95% CI 0.53-0.80). No impact was observed on LO-VAP (RR 0.95; 95% CI 0.54-1.67), 28-day mortality (RR 0.76; 95% CI 0.53-1.09), intubation duration (SMD -0.13; 95% CI -0.46-0.21), or ICU length of stay (SMD -0.22; 95% CI -0.55-0.12). Heterogeneity and the risk of bias were low, with high overall evidence certainty.

Conclusions: In adult patients in coma due to ABI, intravenous β-lactam antibiotics reduce EO-VAP and all-VAP risk.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicina intensiva

自引率

0.00%

发文量